Criticism Of The Nusantara Vaccine Former Minister Of Health Terawan It Is Commonplace, DPR: Notes For Improving Research

JAKARTA - Member of Commission IX DPR Saleh Partaonan Daulay supports the development of the Nusantara Vaccine as a local vaccine made by the nation's children.

He hopes that this vaccine can cover domestic needs after obtaining a permit to use BPOM.

The Nusantara vaccine is a vaccine developed by former Health Minister Terawan Agus Putranto. This vaccine has passed phase two clinical trials. "Because the domestic demand for vaccines is enormous," Saleh told reporters, Thursday, February 25.

Saleh assessed that the development of the Nusantara Vaccine which entered the second phase of clinical trials was quite good because there was a significant movement from the research.

"Because it needs to be continued," said the legislator from North Sumatra.

Questioning the existence of criticism of the Nusantara Vaccine development process, Saleh considered it reasonable. He hopes that criticism can be an input to perfect vaccine research.

"The criticism is that we hope to provide solutions and provide notes that can enhance the research being carried out," said the former chairman of the Muhammadiyah Youth.

Previously, Deputy Chairman of the People's Representative Council (DPR) of the Republic of Indonesia (RI) Coordinator for Economic and Financial Affairs (Korekku) Sufmi Dasco Ahmad visited the Office of the Food and Drug Supervisory Agency (BPOM), Wednesday, February 24.

Dasco said the Nusantara vaccine that was researched and developed by former Health Minister Terawan Agus Putranto had just entered the study stage at the BPOM. He said, currently local vaccines are still in the discussion stage and need further study.

The head of the DPR's COVID-19 Task Force (Task Force) also explained that currently, the Nusantara Vaccine is still in the discussion and study stages, while the Red and White Vaccine has different progress in research institutions.

"Both the Nusantara and the Red and White Vaccines still need further discussion and study," said Dasco in his statement.

For the Nusantara Vaccine, it was developed by Diponegoro University (Undip) scientists in collaboration with PT Rama Emerald Multi Sukses in collaboration with AVITA Biomedical Inc.

Meanwhile, the Red and White Vaccine was developed by the Eijkman Institute and PT Biofarma (Persero). The vaccine is expected to be completed in November 2022.

The development was initiated by a research consortium under the auspices of the Ministry of Research and Technology or the National Research and Innovation Agency (BRIN).